Prestige Consumer Healthcare Hits New 52-Week Low at $49.28

Prestige Consumer Healthcare, Inc. has reached a new 52-week low, trading at USD 49.28 as of May 11, 2026. This marks a significant decline for the small-cap company, which operates within the Pharmaceuticals & Biotechnology industry. Over the past year, Prestige Consumer Healthcare has experienced a performance drop of 22.9%, contrasting sharply with the S&P 500's gain of 30.97%. The company's financial metrics reveal a P/E ratio of 16.00, indicating a valuation that aligns with its peers. However, the lack of dividend yield and a debt-to-equity ratio of 0.54 suggest a cautious approach to financial leverage. Return on equity stands at 10.66%, while the price-to-book ratio is 1.71, reflecting a fair valuation in comparison to historical averages. Recent quarterly results have shown net sales at USD 249.53 million and operating profit at USD 79.42 million, both at their lowest points. The company's long-term growth has been modest, with net sales and operating profit growing at annual rates of 3.13% and 3.08%, respectively, over the last five years. This performance underscores the challenges faced by Prestige Consumer Healthcare in both the near and long term.